Pharmacology Nursing Practice Question Bank
1,200 Original Review Questions with Detailed Learning Rationales
Concept-Aligned with Pharmacology: A Patient-Centered Nursing Process
Approach (12th Edition)
Reference Alignment Notice
This resource is not an official publisher product, instructor resource, examination document, or affiliated
publication.
Reference Source
McCuistion, L. E., DiMaggio, K. V., Winton, M. B., & Yeager, J. J. Pharmacology: A Patient-Centered
Nursing Process Approach (12th ed.). Elsevier.
Page 1
,Coverage
• Chapter 1: Clinical Judgment Measurement Model and the Nursing Process
• Chapter 2: Drug Development and Ethical Considerations
• Chapter 3: Pharmacokinetics and Pharmacodynamics
• Chapter 4: Pharmacogenetics
• Chapter 5: Complementary and Alternative Therapies
• Chapter 6: Pediatric Considerations
• Chapter 7: Geriatric Considerations
• Chapter 8: Drugs in Substance Use Disorder
• Chapter 9: Safety and Quality
• Chapter 10: Drug Administration
• Chapter 11: Drug Labels and Dosage Calculations
• Chapter 12: Fluid Volume and Electrolytes
• Chapter 13: Vitamin and Mineral Replacement
• Chapter 14: Nutritional Support
• Chapter 15: Adrenergic Agonists and Antagonists
• Chapter 16: Cholinergic Agonists and Antagonists
• Chapter 17: Stimulants
• Chapter 18: Depressants
• Chapter 19: Antiseizure Drugs
• Chapter 20: Drugs for Parkinsonism and Alzheimer’s Disease
• Chapter 21: Drugs for Neuromuscular Disorders and Muscle Spasms
• Chapter 22: Antipsychotics and Anxiolytics
• Chapter 23: Antidepressants and Mood Stabilizers
• Chapter 24: Antiinflammatories
• Chapter 25: Analgesics
• Chapter 26: Penicillins, Other Beta-Lactams, and Cephalosporins
• Chapter 27: Macrolides, Oxazolidinones, Lincosamides, Glycopeptides, Ketolides, and Lipopeptides
• Chapter 28: Tetracyclines, Glycylcyclines, Aminoglycosides, and Fluoroquinolones
• Chapter 29: Sulfonamides and Nitroimidazoles Antibiotics
• Chapter 30: Antituberculars, Antifungals, and Antivirals
• Chapter 31: Antimalarials, Anthelmintics, and Peptides
Page 2
,• Chapter 32: HIV- and AIDS-Related Drugs
• Chapter 33: Transplant Drugs
• Chapter 34: Vaccines
• Chapter 35: Anticancer Drugs
• Chapter 36: Targeted Therapies to Treat Cancer
• Chapter 37: Biologic Response Modifiers
• Chapter 38: Upper Respiratory Disorders
• Chapter 39: Lower Respiratory Disorders
• Chapter 40: Cardiac Glycosides, Antianginals, and Antidysrhythmics
• Chapter 41: Diuretics
• Chapter 42: Antihypertensives
• Chapter 43: Anticoagulants, Antiplatelets, and Thrombolytics
• Chapter 44: Antihyperlipidemics and Drugs to Improve Peripheral Blood Flow
• Chapter 45: Gastrointestinal Tract Disorders
• Chapter 46: Antiulcer Drugs
• Chapter 47: Eye and Ear Disorders
• Chapter 48: Dermatologic Disorders
• Chapter 49: Pituitary, Thyroid, Parathyroid, and Adrenal Disorders
• Chapter 50: Antidiabetics
• Chapter 51: Urinary Disorders
• Chapter 52: Pregnancy and Preterm Labor
• Chapter 53: Labor, Delivery, and Postpartum
• Chapter 54: Neonatal and Newborn
• Chapter 55: Women’s Reproductive Health
• Chapter 56: Men’s Reproductive Disorders
• Chapter 57: Sexually Transmitted Infections
• Chapter 58: Adult and Pediatric Emergency Drugs
Page 3
, Chapter 1: Clinical Judgment Measurement Model and the Nursing Process
1. Which mechanism best explains the expected effect of pharmacodynamics?
A. Dose-response relationships vary among patients.
B. Describe what a drug does to the body.
C. Therapeutic and adverse responses.
D. Receptor interaction and downstream physiologic effects determine response.
Answer: D Receptor interaction and downstream physiologic effects determine response.
Detailed rationale: pharmacodynamics is classified as a general pharmacology concept. The key
pharmacologic mechanism is: receptor interaction and downstream physiologic effects determine
response. That action supports the clinical role described as describe what a drug does to the body.
Monitoring and teaching are important for safe use, but they do not define the drug’s mechanism.
Clinical reasoning: first identify exactly what the stem is testingsuch as drug class, mechanism,
indication, expected effect, adverse reaction, contraindication, monitoring priority, or patient
teachingthen select the option that answers that dimension most directly. Safety connection: the correct
response links pharmacology knowledge to prevention of medication error, recognition of toxicity or
deterioration, and appropriate follow-up. Why the distractors are incorrect: some alternatives describe a
related pharmacologic property or safety principle, while others do not answer the clinical dimension
requested or conflict with safe medication-use principles.
2. Which statement about first-pass metabolism indicates that the patient needs additional teaching?
A. “I will follow this teaching: do not substitute routes without authorization.”
B. “I understand the clinical role includes: explain reduced bioavailability of some oral drugs.”
C. “I can ignore this precaution: do not assume oral and IV doses are equivalent.”
D. “I understand my care team may monitor: response after route/formulation changes.”
Answer: C “I can ignore this precaution: do not assume oral and IV doses are equivalent.”
Detailed rationale: The incorrect statement dismisses an important safety point: do not assume oral and
IV doses are equivalent. The other statements appropriately distinguish the drug’s clinical role, patient
teaching, and monitoring. A patient should never be taught to ignore a meaningful precaution. Clinical
reasoning: first identify exactly what the stem is testingsuch as drug class, mechanism, indication,
expected effect, adverse reaction, contraindication, monitoring priority, or patient teachingthen select the
option that answers that dimension most directly. Safety connection: the correct response links
pharmacology knowledge to prevention of medication error, recognition of toxicity or deterioration, and
appropriate follow-up. Why the distractors are incorrect: some alternatives describe a related
pharmacologic property or safety principle, while others do not answer the clinical dimension requested
or conflict with safe medication-use principles.
Page 4
1,200 Original Review Questions with Detailed Learning Rationales
Concept-Aligned with Pharmacology: A Patient-Centered Nursing Process
Approach (12th Edition)
Reference Alignment Notice
This resource is not an official publisher product, instructor resource, examination document, or affiliated
publication.
Reference Source
McCuistion, L. E., DiMaggio, K. V., Winton, M. B., & Yeager, J. J. Pharmacology: A Patient-Centered
Nursing Process Approach (12th ed.). Elsevier.
Page 1
,Coverage
• Chapter 1: Clinical Judgment Measurement Model and the Nursing Process
• Chapter 2: Drug Development and Ethical Considerations
• Chapter 3: Pharmacokinetics and Pharmacodynamics
• Chapter 4: Pharmacogenetics
• Chapter 5: Complementary and Alternative Therapies
• Chapter 6: Pediatric Considerations
• Chapter 7: Geriatric Considerations
• Chapter 8: Drugs in Substance Use Disorder
• Chapter 9: Safety and Quality
• Chapter 10: Drug Administration
• Chapter 11: Drug Labels and Dosage Calculations
• Chapter 12: Fluid Volume and Electrolytes
• Chapter 13: Vitamin and Mineral Replacement
• Chapter 14: Nutritional Support
• Chapter 15: Adrenergic Agonists and Antagonists
• Chapter 16: Cholinergic Agonists and Antagonists
• Chapter 17: Stimulants
• Chapter 18: Depressants
• Chapter 19: Antiseizure Drugs
• Chapter 20: Drugs for Parkinsonism and Alzheimer’s Disease
• Chapter 21: Drugs for Neuromuscular Disorders and Muscle Spasms
• Chapter 22: Antipsychotics and Anxiolytics
• Chapter 23: Antidepressants and Mood Stabilizers
• Chapter 24: Antiinflammatories
• Chapter 25: Analgesics
• Chapter 26: Penicillins, Other Beta-Lactams, and Cephalosporins
• Chapter 27: Macrolides, Oxazolidinones, Lincosamides, Glycopeptides, Ketolides, and Lipopeptides
• Chapter 28: Tetracyclines, Glycylcyclines, Aminoglycosides, and Fluoroquinolones
• Chapter 29: Sulfonamides and Nitroimidazoles Antibiotics
• Chapter 30: Antituberculars, Antifungals, and Antivirals
• Chapter 31: Antimalarials, Anthelmintics, and Peptides
Page 2
,• Chapter 32: HIV- and AIDS-Related Drugs
• Chapter 33: Transplant Drugs
• Chapter 34: Vaccines
• Chapter 35: Anticancer Drugs
• Chapter 36: Targeted Therapies to Treat Cancer
• Chapter 37: Biologic Response Modifiers
• Chapter 38: Upper Respiratory Disorders
• Chapter 39: Lower Respiratory Disorders
• Chapter 40: Cardiac Glycosides, Antianginals, and Antidysrhythmics
• Chapter 41: Diuretics
• Chapter 42: Antihypertensives
• Chapter 43: Anticoagulants, Antiplatelets, and Thrombolytics
• Chapter 44: Antihyperlipidemics and Drugs to Improve Peripheral Blood Flow
• Chapter 45: Gastrointestinal Tract Disorders
• Chapter 46: Antiulcer Drugs
• Chapter 47: Eye and Ear Disorders
• Chapter 48: Dermatologic Disorders
• Chapter 49: Pituitary, Thyroid, Parathyroid, and Adrenal Disorders
• Chapter 50: Antidiabetics
• Chapter 51: Urinary Disorders
• Chapter 52: Pregnancy and Preterm Labor
• Chapter 53: Labor, Delivery, and Postpartum
• Chapter 54: Neonatal and Newborn
• Chapter 55: Women’s Reproductive Health
• Chapter 56: Men’s Reproductive Disorders
• Chapter 57: Sexually Transmitted Infections
• Chapter 58: Adult and Pediatric Emergency Drugs
Page 3
, Chapter 1: Clinical Judgment Measurement Model and the Nursing Process
1. Which mechanism best explains the expected effect of pharmacodynamics?
A. Dose-response relationships vary among patients.
B. Describe what a drug does to the body.
C. Therapeutic and adverse responses.
D. Receptor interaction and downstream physiologic effects determine response.
Answer: D Receptor interaction and downstream physiologic effects determine response.
Detailed rationale: pharmacodynamics is classified as a general pharmacology concept. The key
pharmacologic mechanism is: receptor interaction and downstream physiologic effects determine
response. That action supports the clinical role described as describe what a drug does to the body.
Monitoring and teaching are important for safe use, but they do not define the drug’s mechanism.
Clinical reasoning: first identify exactly what the stem is testingsuch as drug class, mechanism,
indication, expected effect, adverse reaction, contraindication, monitoring priority, or patient
teachingthen select the option that answers that dimension most directly. Safety connection: the correct
response links pharmacology knowledge to prevention of medication error, recognition of toxicity or
deterioration, and appropriate follow-up. Why the distractors are incorrect: some alternatives describe a
related pharmacologic property or safety principle, while others do not answer the clinical dimension
requested or conflict with safe medication-use principles.
2. Which statement about first-pass metabolism indicates that the patient needs additional teaching?
A. “I will follow this teaching: do not substitute routes without authorization.”
B. “I understand the clinical role includes: explain reduced bioavailability of some oral drugs.”
C. “I can ignore this precaution: do not assume oral and IV doses are equivalent.”
D. “I understand my care team may monitor: response after route/formulation changes.”
Answer: C “I can ignore this precaution: do not assume oral and IV doses are equivalent.”
Detailed rationale: The incorrect statement dismisses an important safety point: do not assume oral and
IV doses are equivalent. The other statements appropriately distinguish the drug’s clinical role, patient
teaching, and monitoring. A patient should never be taught to ignore a meaningful precaution. Clinical
reasoning: first identify exactly what the stem is testingsuch as drug class, mechanism, indication,
expected effect, adverse reaction, contraindication, monitoring priority, or patient teachingthen select the
option that answers that dimension most directly. Safety connection: the correct response links
pharmacology knowledge to prevention of medication error, recognition of toxicity or deterioration, and
appropriate follow-up. Why the distractors are incorrect: some alternatives describe a related
pharmacologic property or safety principle, while others do not answer the clinical dimension requested
or conflict with safe medication-use principles.
Page 4
